One weird monster is better than twenty maybe-stocks.

Focused post-Blade medical infrastructure platform for organ-transplant logistics, surgical recovery, organ placement, NRP/perfusion, staffing, and equipment. The market may still price SRTA as legacy passenger/eVTOL-adjacent aviation or low-margin logistics, while the upside case is a one-call mission-critical transplant infrastructure consolidator with network-density advantages, clinical-service optionality, improving cash conversion, and bolt-on M&A evidence.

Global SMB cross-border commerce infrastructure mispriced as a commodity/rate-sensitive fintech. Payoneer combines regulated local rails, marketplace relationships, multi-currency accounts, AP/AR, working capital, and payout workflows across 7,000+ corridors and nearly 2M active customers. If core volume reaccelerates and margins scale, it has a plausible 5-10 year path to multi-billion revenue and $15B+ equity value.

Founder-led national infrastructure engineering/services consolidator in a fragmented AEC market. The market may price Bowman as a cyclical consultant, while the upside case is a Strata-like hidden workflow platform: local mission-critical relationships plus national scale, geospatial/automation tooling, public infrastructure tailwinds, and a bolt-on acquisition flywheel.

Computational chemistry / molecular-design software platform with drug-discovery optionality; could become mission-critical R&D infrastructure if AI-enabled molecular simulation adoption broadens.

5–10x plausible but high risk if software/platform revenue scales to $500–700M+, margins become software-like, and pipeline/milestone economics add upside from a sub-$1B market cap.

AI-native custom-manufacturing marketplace that could become the procurement and execution infrastructure layer for fragmented machine shops and enterprise buyers. If Xometry’s buyer/supplier network, instant quoting, enterprise workflows, and Siemens Xcelerator partnership create a durable digital thread from design to delivered parts, it has a plausible 5-10 year path to multi-billion revenue and a 5-10x equity outcome.

Healthcare workflow software consolidator: EHR, patient flow, care coordination, clinical workflow, workforce and patient-engagement tools. The market may view VitalHub as a small Canadian healthcare-software roll-up, while the asymmetric thesis is a mission-critical healthcare operating layer with sticky regulated workflows, high gross margins, organic ARR growth, cross-sell, and disciplined tuck-in M&A across fragmented health systems.

Mission-critical building-systems infrastructure platform for mechanical, electrical, plumbing, and controls systems. The market may treat LMB as a cyclical contractor; the better thesis is a higher-quality owner-direct service platform for healthcare, industrial, data-center, life-sciences, education, and other uptime-critical facilities, with recurring relationships, margin mix shift, local density and bolt-on consolidation optionality.

Focused GovTech/public-sector workflow software platform after divesting merchant services and healthcare RCM. The market may still view IIIV as a messy payments roll-up with slow headline growth; the asymmetric thesis is a mission-critical, regulated public-sector operating layer across courts/public safety, public administration/ERP, transportation, utilities, and education, with 5,000+ contracted customers, recurring revenue, embedded payments, sticky implementations, and a long fragmented modernization/M&A runway.

Small public buy-and-build platform for commercial and industrial laundry infrastructure: equipment distribution, facility design/planning, installation, parts, maintenance, repair, boiler/mechanical systems, water heating, power generation, and water-reuse systems. The market may price EVI as a low-margin equipment distributor, while the asymmetric thesis is a one-call mission-critical infrastructure and service platform for fragmented laundry/boiler workflows serving healthcare, hospitality, government, industrial, correctional, education, food/beverage, cruise and retail customers.

Identity-intelligence and risk/compliance data platform hiding in a small-cap wrapper. Red Violet's idiCORE/IDI and FOREWARN products sit inside fraud prevention, identity verification/authentication, due diligence, legislative compliance, debt recovery, law-enforcement/government, real-estate safety, collections and corporate-security workflows. The market may price RDVT as an expensive niche data vendor; the asymmetric thesis is a high-gross-margin, cloud-native identity graph and workflow rail where more data, more customers, API/batch integrations and specialized compliance use cases compound into a mission-critical fraud/risk infrastructure platform.

Food traceability and supplier-compliance rails hiding inside a tiny profitable SaaS/network company. ReposiTrak operates a hub-and-spoke B2B platform where retailers/wholesalers pull suppliers into compliance, traceability and supply-chain workflows. The market may punish flat near-term revenue and delayed FSMA 204 enforcement, while the upside case is that industry-led traceability requirements, recall readiness, supplier records, Touchless Traceability patents/processes and a growing food-supply network turn TRAK into a mission-critical compliance/traceability operating layer for fragmented grocery, wholesale, foodservice and supplier ecosystems.

Mission-critical supply-chain execution software for healthcare and complex distribution hiding in a small Canadian public company. The market may view Tecsys as a slow, niche WMS/vendor-services company with modest GAAP profit; the asymmetric thesis is a sticky operating layer for hospital supply chains, pharmacies/health systems and complex distributors where inventory visibility, compliance, replenishment, warehouse execution and integration reliability matter. If Elite SaaS migration, healthcare penetration, AI-driven TecsysIQ workflows and Gartner-recognized WMS credibility compound, TCS can become a scarce healthcare/distribution supply-chain infrastructure platform.